Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

FDA accepts for review Forest and Cypress' NDA for milnacipran for fibromyalgia

Feb. 27, 2008

Positive preclinical results of S-0139 in ischemic stroke

Feb. 27, 2008

Recent patents report new psychopharmacologic agents

Feb. 26, 2008

Phase III AZ-004 trial begins in patients with schizophrenia or bipolar disorder

Feb. 26, 2008

Rosiglitazone neuroprotective mechanism in experimental stroke elucidated

Feb. 26, 2008

Reduced spinal cord opioid receptor mRNA and antinociception in MS mouse model

Feb. 26, 2008

MK-0343 has different effects on healthy volunteers than lorazepam

Feb. 26, 2008

Allon Therapeutics adds Alzheimer's patients to ongoing phase II clinical trial of AL-108

Feb. 25, 2008

Novel 5-HT6 receptor antagonist potentially useful as cognition enhancer

Feb. 25, 2008

New therapeutic agents for neurological disorders reported in recent patents

Feb. 25, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...